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Objectives: Although comorbidities play an essential role in risk adjustment and outcomes measurement, there is little
consensus regarding the best source of this data. The aim of this study was to identify general patient-reported morbidity
instruments and their measurement properties.
Methods: A systematic review was conducted using multiple electronic databases (Embase, Medline, Cochrane Central, and
Web of Science) from inception to March 2018. Articles focusing primarily on the development or subsequent validation of a
patient-reported morbidity instrument were included. After including relevant articles, the measurement properties of each
morbidity instrument were extracted by 2 investigators for narrative synthesis.
Results: A total of 1005 articles were screened, of which 34 eligible articles were ultimately included. The most widely
assessed instruments were the Self-Reported Charlson Comorbidity Index (n = 7), the Self-Administered Comorbidity
Questionnaire (n = 3), and the Disease Burden Morbidity Assessment (n = 3). The most commonly included conditions
were diabetes, hypertension, and myocardial infarction. Studies demonstrated substantial variability in item-level
reliability versus the gold standard medical record review (k range 0.66-0.86), meaning that the accuracy of the self-
reported comorbidity data is dependent on the selected morbidity.
Conclusions: The Self-Reported Charlson Comorbidity Index and the Self-Administered Comorbidity Questionnaire were the
most frequently cited instruments. Significant variability was observed in reliability per comorbid condition of patient-
reported morbidity questionnaires. Further research is needed to determine whether patient-reported morbidity data
should be used to bolster medical records data or serve as a stand-alone entity when risk adjusting observational
outcomes data.
Keywords: comorbidity, health services, morbidity, patient report, psychometrics, self-report, surveys and questionnaires.
VALUE HEALTH. 2020; -(-):-–-Introduction
Value-based healthcare (VBHC) initiatives rely on risk adjust-
ment to compare patient populations across hospitals. In addition
to understanding the index disease of interest, comorbid condi-
tions are necessary for case-mix adjustment. “Morbidity” is
defined here as the presence of medical conditions. Clinicians are
increasingly grappling with the challenges of treating patients
with multiple co-occurring diseases (multimorbidity). In addition
to treatment difficulties, multimorbidity is often associated withof interest: Swami was a paid employee at the International Consortium for
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doi.org/10.1016/j.jval.2020.02.006worse outcomes including decreased quality of life, psychological
distress, longer hospital stays, more postoperative complications,
higher cost of care, and higher mortality.1,2
To identify opportunities for outcomes improvement, registries
and groups like the International Consortium for Healthcare
Outcomes Measurement (ICHOM) have attempted to standardize
and compare observational data across hospitals.3 These
comparative studies often rely on risk adjustment algorithms to
account for clinical differences in patient populations.4 In
analyzing a changing medical landscape with moreHealth Outcomes Measurement (ICHOM) during the development of this paper.
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2 VALUE IN HEALTH - 2020multimorbidity patients, reliable morbidity data has increasingly
become a focal point for fair benchmarking as part of the shift
toward VBHC.
Accurate inclusion of comorbidities in large data sets has
proven to be a vexing problem. Although morbidity plays a crucial
role in risk adjustment, risk stratification, and outcomes mea-
surement, there is little consensus regarding the best source of
this data. Comparisons of morbidity data from different sources
have displayed significant variations.5 Notable inconsistencies
have been observed when morbidity data is collected from
administrative sources, such as claims data.6 Administrative data
generally underreports comorbid conditions, leading to a lack of
accounting for overall level of sickness of the patient.7-9 Although
some studies have shown more accurate information in hospital
chart reviews, concerns arise regarding the burden of collection
and the feasibility of wide-scale use.10,11
To obtain more accurate morbidity data feasibly, clinicians
have increasingly turned to patient-reported instruments as a
potential alternative.12,13 The objective of this study was to pro-
vide a comprehensive evidence base of validated patient-reported
morbidity instruments to aid in the selection of these instruments
for use in clinical practice. Although many disease-specific
morbidity instruments exist, our study examined questionnaires
applicable to the broader patient population to allow for broader
implementation across a healthcare system.Methods
Design and Rationale
Risk adjustment for the comparison of outcomes data across
international healthcare centers relies on the accurate capture of
predictor variables such as extent of morbidity. Because standard
outcome sets could be used among health institutions with no or
different electronic medical record and administrative data
structures, a systematic review was conducted according to the
Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines14 of studies about the develop-
ment or subsequent validation of self-reported comorbidity
assessments.
Literature Search
An exhaustive search strategy was developed in Embase.com
by a medical librarian experienced in systematic review
searches.15 To retrieve articles about the validation of question-
naires on comorbidity, the search strategy combined thesaurus
terms (Emtree terms for Embase and MeSH terms for Medline)
with terms in the title or abstract for 3 elements: comorbidity,
questionnaires, and validation or reliability.
The search strategy for Embase was optimized to find all
potentially relevant terms and then translated to Medline (Ovid),
Cochrane CENTRAL, and Web of Science Core Collection.16 Addi-
tional references were retrieved from Google Scholar (the first 100
references as sorted by relevance), literature lists of relevant re-
views, and included references. Abstracts needed to be in English,
but therewere no restrictions on the language of themanuscript or
country of publication in the search strategy. The databases were
last searched on March 5, 2018. The full search strategies for all the
databases are included in the online Appendix in Supplemental
Materials found at https://doi.org/10.1016/j.jval.2020.02.006.
Study Selection
The inclusion criterion for studies was a primary focus on the
development or subsequent validation (eg, reliability andprediction/association with outcomes) of an instrument for col-
lecting information on the presence of morbidity directly from the
patient.
The exclusion criteria were:
B lack of any methodological description of instrument develop-
ment (validation and/or reliability of instrument)
B description of the use of a patient-reported comorbidity ques-
tionnaire for risk-adjustment purposes or for deriving health
utilities
B focus in the patient-reported morbidity instrument on a subset
of specific conditions (based on nosologic criteria), thereby
making the instrument not generalizable to a larger patient
population (eg, a list of mental health comorbidities for psy-
chiatric patients)
The search results were deduplicated17 and then imported into
Covidence (www.covidence.org, Melbourne, Australia), a
Cochrane technology web-based platform developed specifically
to screen and track articles through the inclusion and exclusion
criteria process of a systematic review. In Covidence, the titles and
abstracts of each reference were independently screened for
relevance by 2 reviewers. The screening phase was conducted in
the following order:
1. The first screening was based on the title and abstract. In the
event that the article’s aim did not meet the inclusion criteria
but nevertheless mentioned a patient-reported medical co-
morbidity questionnaire, the full text was reviewed to deter-
mine the instrument used and references were further
screened for any potential missing articles on the comorbidity
questionnaire.
2. The second screening was based on the full-text assessment of
retained articles. Studies that still did not meet our inclusion
criterion were subsequently removed.
If the authors had any disagreements on article eligibility
during the first screening, the study in question would be
screened in a full-text version. Consensus on the inclusivity of
selected articles was ultimately reached by the authors.
Included Comorbidities
The number of comorbidities, as well as a list of included co-
morbid conditions, was evaluated for every survey instrument.
Additional survey questions, such as those evaluating the condi-
tion severity (impact on daily activities/functional status) or
medication use for a comorbidity, were also noted.
Reliability
Measures of reliability (eg, test–retest reliability; patient-
report vs other data sources such as medical records, adminis-
trative data, or laboratory testing) at either item-level or overall
instrument level were catalogued for all studies. Because of the
anticipated heterogeneity in the reporting between the studies,
both reliability-specific values (intraclass correlation coefficient
[ICC] and Kappa [k] values) and other measures of the morbidity
instrument’s performance (Spearman correlation coefficient,
sensitivity/specificity, and positive and negative predictive values)
were included. The kappa values were measured based on the
presence of the condition in the self-reported instrument versus
the medical record (or administrative record), which was
considered the gold standard. The articles mention that reporting
a condition by self-report that is absent in the medical record
could also imply a deficiency with the medical record. Kappa
-- 3values .0.80 indicate excellent agreement, 0.61 to 0.80 good
agreement, 0.41 to 0.60 moderate agreement, 0.21 to 0.40 fair
agreement, and , 0.20 poor agreement.18 Spearman correlation
coefficients are categorized as #0.20 (poor), 0.30 to 0.59 (fair),
0.60 to 0.79 (moderate), and . 0.80 (strong).19
Evaluated Outcomes
All instances where patient-reported morbidity instruments
were used to assess association with or predict certain outcomes
as part of the validation study were documented for this review.
Examples of the outcome metrics included are mortality, disease
response, patient-reported outcome measures (PROMs), adverse
events and other events of interest, and healthcare utilization/
costs, as per the categories of outcomes used in the Agency for
Healthcare Research and Quality (AHRQ) Outcome Measures
Framework (OMF).20
Questionnaire Length, Duration, Responsiveness, and
Utilization
The length (number of items/questions) of the instrument and
duration of completion was documented, when available, as was
the route of administration (self-administration vs administration
by a clinical or research associate). Finally, the number of times the
paper had been cited in Web of Science was also noted.
Results
Included Studies
Figure 1 details the search and inclusion strategy. In total, 1005
studies met our search criteria; 70 studies met our criteria for
inclusion in the full-text assessment. Thirty-six studies were
eliminated after the full-text review, leaving 34 studies for inclu-
sion in this systematic review.
A summarized overview of all the included articles in this
systematic review is included in Table 1. Descriptive characteris-
tics, reliability, validity, and evaluated outcomes of morbidity in-
struments are shown in Table 2.21-67Figure 1. Flowchart of relevant article selection.
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(n  = 34)Included Patient-Reported Morbidity Instruments
Ten original patient-reported morbidity instruments were
identified, with most of these development studies being con-
ducted in the United States. The instruments considered originals
were: the Self-Reported Charlson Comorbidity Index (SR-CCI),11
the Self-Administered Comorbidity Questionnaire (SCQ),27 the
Disease Burden Morbidity Assessment (DBMA),32 the Comorbidity
Symptom Scale (CmSS),38 the Patient Self-Administered Health
History Questionnaire,47 the Multi-Morbidity Assessment Ques-
tionnaire for Primary Care (MAQ-PC),59 the Patient-Based Co-
morbidity Index (CI),64 the Health Impact Index (HII),50 the Seattle
Index of Comorbidity (SIC),48 and an unnamed prognostic index
(including comorbidities).60 The SR-CCI and SCQ instruments were
the most frequently cited. Other included articles were translation
and cross-cultural adaptation studies, variations of these ques-
tionnaires (eg, with a small number of items added or removed),
or validation studies.
Presence of Specific Conditions and Related Assessments
Conditions that were most commonly included in the patient-
reported morbidity instruments were diabetes, hypertension,
myocardial infarction, and stroke (see Table 2). The question
regarding the presence or absence of specific comorbidities was
presented in multiple ways, including:
 “Do you have or have you ever had.?”32,34,41,50,60,65
 “Has a doctor ever told you that you have.?”5,44,45,48,55,59,60
 “Do have you any of the following problems?”27,28,30,45
Most instruments had close-ended response alternatives for
each condition listed. Some questionnaires had an additional free-
text item for patients to report additional comorbidities that were
not listed in the instrument.27,33,47,52,63
Several instruments included additional questions regarding
the severity of the conditions, such as, “Does it limit your
activities?”5,27,28,30,32,34 or regarding active treatment, for
example, “Do you receive treatment for it?”5,27,28,30,44) identified
 Medline Epub, PsycInfo,
e Central, Cinahl)
Excluded titles/ abstracts based on
aim of article (n = 935)
Excluded articles based on
exclusion criteria (studies without
validation/ reliability measurement
of comorbidity instrument; disease-
specific comorbidities) and/ or study
design (editorial, review) (n = 36)
 assessment
)
ded
Table 1. Summarized overview of included studies.
Patient-reported
morbidity
instruments
Selected article
and country
of origin
Availability of
reliability data
Evaluated
outcomes
Method of
questionnaire
administration
Time to
questionnaire
completion
Number
of Citations
Patient-Reported
Charlson
Comorbidity
Index
Katz, 1996*,†
United States
Item-level: 1
Overall: 1
Mortality: 2
PROM: 2
Healthcare
utilization: 1
Self- or interviewer-
administered
10 minutes 758
Susser, 2008*
Canada
Item-level: 1
Overall: 1
Mortality: 2
PROM: 1
Healthcare
utilization: 2
Self-administered
or filled out by proxy
- 19
Corser, 2008*
United States
Item-level: 1
Overall: 1
Mortality: 2
PROM: 2
Healthcare
utilization: 2
Interviewer-administered - 53
Olomu, 2012*
United States
Item-level: 2
Overall: 2
Mortality: 2
PROM: 1
Healthcare
utilization: 2
Interviewer-administered - 23
Ng, 2015*
Singapore
Item-level: 1
Overall: 1
Mortality: 2
PROM: 1
Healthcare
utilization: 2
Self- or interviewer-
administered
15 minutes 5
Habbous, 2013*
Canada
Item-level: 1
Overall: 1
Mortality: 1
PROM: 2
Healthcare
utilization: -
Self-administered - 11
Chaudhry, 2005*
United States
Item-level: 1
Overall: 2
Mortality: 1
PROM: 2
Healthcare
utilization: 1
Self-administered 1 minute 172
Self-Reported
Comorbidity
Questionnaire
Sangha, 2003*,†
United States
Item-level: 1
Overall: 1
Mortality: 2
PROM: 1
Healthcare
utilization: 1
Self-administered - 757
Stolwijk, 2014*
Netherlands/
Belgium
Item-level: 1
Overall: 1
Mortality: 2
PROM: 1
Healthcare
utilization: 2
Self-administered - 17
Robinski, 2016*
Germany
Item-level: 1
Overall: 2
Mortality: 2
PROM: 1
Healthcare
utilization: 2
Self-administered - 2
Disease Burden
Morbidity
Assessment
Bayliss, 2005†
United States
Item-level: 1
Overall: 2
Mortality: 2
PROM: 1
Healthcare
utilization: 2
Self-administered - 133
Poitras, 2012
Canada
Item-level: 1
Overall: 2
Mortality: 2
PROM: 2
Healthcare
utilization: 2
Self-administered ,15 minutes 19
Wijers, 2017
Spain
Item-level: 2
Overall: 2
Mortality: 2
PROM: 1
Healthcare
utilization: 2
Self-administered - 2
Simpson, 2004
United States
Item-level: 1
Overall: 2
Mortality: 2
PROM: 2
Healthcare
utilization: 2
Self-administered - 214
Comorbidity
Symptom
Scale
Crabtree, 2000*
England
Item-level: 2
Overall: 2
Mortality: 2
PROM: 1
Healthcare
utilization: 2
Interviewer-administered ,10 minutes 29
continued on next page
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Table 1. Continued
Patient-reported
morbidity
instruments
Selected article
and country
of origin
Availability of
reliability data
Evaluated
outcomes
Method of
questionnaire
administration
Time to
questionnaire
completion
Number
of Citations
De-Loyde, 2015
Australia
Item-level: 2
Overall: 2
Mortality: 2
PROM: 2
Healthcare
utilization: 2
Self-administered - 10
Gad, 2012
United States
Item-level: 1
Overall: 2
Mortality: 2
PROM: 2
Healthcare
utilization: 2
Self-administered - 3
Hansen, 2014
Germany
Item-level: 1
Overall: 2
Mortality: 2
PROM: 2
Healthcare
utilization: 2
Interviewer-administered - -
Horton, 2010
Canada/United
States
Item-level: 1
Overall: 2
Mortality: 2
PROM: 2
Healthcare
utilization: 2
Self-administered 11 minutes (mean) 63
Questionnaire from
CALAS study
Iecovich, 2013
Israel
Item-level: 1
Overall: 1
Mortality: 2
PROM: 2
Healthcare
utilization: 2
Interviewer-administered 30 – 45 minutes 1
Klabunde, 2006
United States
Item-level: –
Overall: –
Mortality: 2
PROM: 2
Healthcare
utilization: 2
Self-administered - 114
Boissonnault, 2005
United States
Item-level: 1
Overall: 1
Mortality: 2
PROM: 2
Healthcare
utilization: 2
Self-administered - 15
Seattle Index of
Comorbidity
Fan, 2002*
United States
Item-level: 2
Overall: 2
Mortality: 1
PROM: 1
Healthcare
utilization: 1
Self-administered - 123
Health Impact
Index
Lorem, 2016*
Norway
Item-level: 2
Overall: 1
Mortality: 2
PROM: 1
Healthcare
utilization: 2
Self-administered - 4
Lucke, 2016
Germany
Item-level: 1
Overall: 1
Mortality: 2
PROM: 2
Healthcare
utilization: 2
Self-administered - 12
Cornell Medical
Index
Md Yusof, 2010*
United Kingdom
Item-level: 2
Overall: 1
Mortality: 1
PROM: 2
Healthcare
utilization: 2
Self-administered - 2
Questionnaire from
CHOICE study
Merkin, 2007
United States
Item-level: 1
Overall: 2
Mortality: 2
PROM: 2
Healthcare
utilization: 2
- - 70
Questionnaire from
AHEAD study
Mukerji, 2007
United States
Item-level: 1
Overall: 1
Mortality: 2
PROM: 2
Healthcare
utilization: 2
Self-administered
or interviewer
administered
- 41
Paleri, 2002*
United Kingdom
Item-level: 1
Overall: 2
Mortality: 2
PROM: 2
Healthcare
utilization: 2
Self-administered 8.3 minutes 22
Multi-Morbidity
Assessment
Questionnaire
for Primary Care
Pati, 2016
India
Item-level: 1
Overall: 2
Mortality:
PROM:
Healthcare
utilization:
- 20 – 25 minutes 5
continued on next page
-- 5
Table 1. Continued
Patient-reported
morbidity
instruments
Selected article
and country
of origin
Availability of
reliability data
Evaluated
outcomes
Method of
questionnaire
administration
Time to
questionnaire
completion
Number
of Citations
Lee, 2006*
United States
Item-level: 2
Overall: 2
Mortality: 1
PROM: 2
Healthcare
utilization: 2
Interviewer-administered - 416
Self-Report
Comorbidity
Voaklander, 2004*
Canada
Item-level: 2
Overall: 1
Mortality: 2
PROM: 1
Healthcare
utilization: 1
- - 12
(Patient-Based)
Comorbidity Index
Selim, 2004*
United States
Item-level: 2
Overall: 2
Mortality: 1
PROM: 1
Healthcare
utilization: 1
Interviewer-administered - 150
Questionnaire
from LACE study
Vigen, 2016
United States
Item-level: 1
Overall: 2
Mortality: 1
PROM: 2
Healthcare
utilization: 2
Self- or interviewer-
administered
- 7
Note. 1 = described in study; 2 = unknown/not described in study
AHEAD indicates Action for Health in Diabetes; CALAS, Cross-Sectional and Longitudinal Aging Study; CHOICE, Choices for Healthy Outcomes in Caring for End-stage
renal disease study; LACE, Life After Cancer Epidemiology study; PROM, patient-reported outcome measures.
*Instrument associated with an index
†Main developmental study
6 VALUE IN HEALTH - 2020Instrument Administration, Length, Duration, and
Responsiveness
Nineteen studies had self-administered questionnaires (either in
mailed/writtenorelectronic form),5,25-28,30,32,33,34,36,39,41,44,47,48,50,52,54,57
whereas 8 studies had questionnaires that were administered verbally
by a clinical/research associate (either face-to-face or by
phone)12,22,38,42,45,60,64 and 4 studies reported both administration
methods.9,11,65,24 Of the associate-administered surveys, itwas not clear
whether clarifying questions were allowed or used in nearly all of the
studies. Five studies9,11,24,57,65 had comorbidity questionnaires that
couldeitherbeself-administeredoradministeredbyan interviewer (eg,
associate or other proxy) if needed (eg, for patient illiteracy).
The length of the instruments varied from 4 items65 to 195
items54 (divided over multiple physical and mental sections). Nine
studies mentioned the duration to complete the questionnaire,
which ranged from 1 minute26 to 45 minutes.45 Response rates
were provided in 9 studies ranging from 28%32 to 99%.30
Reliability and Concordance with Other Data Sources
Test–retest reliability was described in 7 studies5,11,27,33,38,47,59
(data not shown), mostly measured by the intraclass correlation
or Spearman correlation coefficients. The amount of patients on
which it was tested ranged from 2611,27 to 103.2 The interval
period between both measurements varied from 24 hours11,27,47 to
4 weeks.38 The overall Spearman correlation coefficients for
patient-reported comorbidity questionnaires ranged from 0.7311
(moderate reliability) to 0.87 (strong reliability),38 whereas the
intraclass correlation coefficients ranged from 0.8633 to 0.97.59
Whole instrument and item-level concordance of patient-
reported morbidity scores with information from other data
sources, either medical records or medical record-derived co-
morbidity indices, were most frequently assessed (see Table 2).
Spearman correlation coefficients for the relationship between
patient-reported morbidity scores and composite scores from
other data sources ranged from r = 0.24 (14 conditions)28 to r =
0.70 (18 conditions).11 In studies measuring Kappa coefficients, k
values were notably higher for agreement with medical records (krange: 0.56-0.69)44,47 as opposed to agreement with medical
record-derived morbidity indices (k range: 0.37-0.50).25,57
Administrative data were also used as a comparative data source
in a number of studies,9,26,45,52,63 which generally demonstrated
poor agreement.9,45,63
Item-level (single condition) was the most commonly reported
form of concordance assessment, mostly measured against med-
ical records or derived morbidity indices. A striking observation
was that diabetes, as a comorbidity questionnaire item, had the
highest Kappa value across included
studies.24,26,30,39,41,42,44,45,55,57,65 Most included studies had a
substantially wide k value range,22,24,25,26,27,28,30,36,41,42,44,45,55,57 in
general from 0.6627 to 0.86.28
Association with Health and Healthcare Outcomes
A number of studies assessed the association between patient-
reported instrument scores and mortality, patient-reported
outcome measures, and healthcare utilization. Because none of
the included studies evaluated their instrument against all 3
outcomes, we provided some examples in this paragraph to
demonstrate the directionality of the associations.
Some studies assessed the relationship between patient-
reported instrument scores and mortality or
survival.25,26,48,54,60,64,65 Habbous et al25 demonstrated a signif-
icant relation between the patient-reported Charlson Comor-
bidity Index (CCI) and overall survival, with the presence of at
least 2 comorbidities being associated with worse survival
(hazard ratio [HR] = 1.62, P=.003). Nevertheless, this relation was
stronger for the nonpatient-reported, medical record-derived CCI
(HR = 2.60). Only a few studies developed prediction models for
all-cause mortality with patient-reported comorbidity in-
struments, either in combination with other predictors such as
demographic variables60 or by themselves.26,48 Fan et al48
developed a prediction model with the Seattle Index of Comor-
bidity (SIC) and estimated an area under the curve (AUC) = 0.71
for all-cause mortality at 2 years follow-up, whereas Lee et al60
estimated an AUC = 0.82 of a different model (including sex,
Table 2. Detailed overview of included studies.
Items Study population (n) Item-level reliability vs other
data sources
Overall instrument reliability
vs other data sources
Evaluated outcome(s)
Katz11 AIDS
Any tumor
Cerebrovascular disease
Chronic pulmonary disease
Congestive heart failure
Connective tissue disease
Dementia
Diabetes (end-organ damage)
Diabetes (mild to moderate)
Hemiplegia
Leukemia
Liver disease
Lymphoma
Metastatic tumor
Moderate/severe renal disease
Myocardial infarction
Peripheral vascular disease
Ulcer disease
170 inpatients from 6 care units
(3 medical and 3 surgical) at 1
hospital.
Characteristics:
Female 55%
Mean age 65.3 years (6 SD 8.8)
Caucasian 82%
College level or higher 50%
Surgical 54%
Comparison: Medical record-
derived CCI
Results:
Kappa: 0.35 (ulcer disease/
diabetes with end-organ
damage) – 0.85 (leukemia)
Sensitivity:
Specificity: -
PPV: -
NPV: -
Agreement between self-
reported CCI and medical
record-derived CCI ranged from
83% (any tumor) to 100% (AIDS).
Comparison: Medical record-
derived CCI
Results:
Self-reported CCI score was
higher versus medical-record
derived CCI (1.99 6 SD 2.13 vs
1.59 6 SD 1.80, P , .01)
Spearman r range 0.63 (P =
.0001) (full index) - 0.70 (P =
.0001) (when the solid tumor
item was excluded from the
analysis)
Measured in 49 and 56
patients on medical and
surgical service
respectively.
Results:
Mortality: -
PROM: -
Healthcare utilization:
Hospitalizations in last
year: Spearman r range
0.17-0.31, P , .05
Number of prescription
medication: Spearman r
range 0.26-0.44, P , .05
Hospital charges during
admission: Spearman r
range 0.09-0.26, P , .05)
Length of stay: Spearman r
range 0.15-0.20
Susser9 As per Katz 520 elderly patients ready to be
discharged home from the ER.
Data from a previously
published RCT.21
Characteristics:
Female 60%
Age group .75 years 57%
Comparison: Administrative
data-derived CCI
Results:
Kappa: Highest k = 0.55 (chronic
pulmonary disease). Individual
Kappa values with range were
not described for all conditions.
Sensitivity: -
Specificity: -
PPV: -
NPV: -
Four conditions were reported
more frequently by self-report
(myocardial infarction, ulcer
disease, diabetes with end-
organ damage, and connective
tissue disease), whereas 5
(hemiplegia, mild-moderate
diabetes, solid tumor,
lymphoma, and dementia) were
more frequently reported in
administrative data.
Comparison: Administrative
data-derived CCI
Results:
Poor agreement between self-
reported and administrative
data-derived CCI, indicated by an
(overall) ICC = 0.43 (95% CI 0.40-
0.47).
Comparison:
Administrative data-
derived CCI
Results:
Mortality: -
PROM:
ADL (functional decline):
predictive ability of self-
reported vs administrative
data-derived CCI was
measured with
unweighted (for sampling)
AUC = 0.51 vs AUC = 0.54
and weighted AUC = 0.54
vs AUC = 0.50, P . .05)
Healthcare utilization:
Hospital days: self-
reported vs administrative
data-derived CCI was
measured with
unweighted AUC = 0.63 vs
AUC = 0.63 and weighted
AUC = 0.68 vs AUC = 0.69, P
. .05)
ER visits: unweighted AUC
= 0.64 vs AUC = 0.65 and
weighted AUC = 0.67 vs
AUC = 0.63, P . .05)
Corser22 As per Katz 525 patients admitted for acute
coronary syndrome in 5
hospitals.
Characteristics:
Female 36.4%
Mean age 59.73 years (6 SD 12)
Caucasian 84.4%
College level or higher 43.8%
Comparison: Medical record-
derived CCI
Results:
Kappa: 0.07 (CTD, RA) –0.80
(diabetes). Only conditions with
a prevalence of at least 3% (in
each data source) were included
in the Kappa analysis.
Sensitivity: -
Specificity: -
PPV: -
NPV: -
Comparison: Medical record-
derived CCI
Results:
Self-reported CCI (composite)
scores were higher than medical
record-derived CCI scores (mean
1.78 6 SD 1.99 vs mean 1.27 6
SD 1.43).
Correlation between self-
reported and medical record-
derived CCI composite scores
were fair (Spearman r = 0.57, P,
.01).
-
continued on next page
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Table 2. Continued
Items Study population (n) Item-level reliability vs other
data sources
Overall instrument reliability
vs other data sources
Evaluated outcome(s)
Olomu12 As per Katz 525 patients admitted for acute
coronary syndrome in 5
hospitals. Data from a previously
published RCT.23
Characteristics:
Female 36.4%
Caucasian 84.4%
College level or higher 43.8%
- - Comparison: Medical
record-derived CCI.
Results:
Mortality: -
PROM:
ASI (functional capacity):
Prediction at 3 months was
slightly better with SCQ vs
the CCI (R2 = 0.340, P ,
.0005 vs R2=0.331, P ,
.0035), whereas it was
slightly better with CCI vs
SCQ (R2 = 0.370, P , .0005
vs R2=0.358, P , .0005) at 8
months.
EQ-5D (health-related
quality of life): Only the
SCQ significantly predicted
EQ-5D scores at 3 and 8
months (R2 = 0.288 and R2
= 0.265, P , .0005),
whereas the CCI did not (R2
= 0.262, P . .201 and R2=
0.245, P . .132).
Healthcare utilization: -
Ng24 As per Katz 301 rheumatic patients from 1
tertiary hospital.
Characteristics:
Female 61.5%
Median age 51 years (21-79)
Chinese 68.8%
College level or higher 54.7%
Comparison: Medical record-
derived CCI
Results:
Kappa: 0.189 (diabetes with end-
organ damage) – 0.764
(diabetes). Kappa values was
only calculated for 8 of 18
conditions that did not have any
cell values of zero.
Sensitivity: 33.3 (diabetes with
end-organ damage) – 100%
(myocardial infarction)
Specificity: 58.9 (CTD, RA) –
99.1% (CVA)
PPV: -
NPV: -
Agreement between self-
reported CCI and medical
record-derived CCI ranged from
74.1% (CTD/ RA) to 100%
(leukemia, lymphoma,
metastatic solid tumor, AIDS).
Comparison: Medical record-
derived CCI
Results:
Median self-reported composite
CCI scores were higher than the
medical record-derived CCI
scores, indicating that conditions
were generally reported more
frequently by self-report than
EHR review.
Self-reported composite CCI
scores had moderate agreement
(ICC = 0.513, P , .001) and
strong correlation (Spearman r =
0.570, P , .001) with the medical
record-derived CCI scores.
Comparison: Medical
record-derived CCI
Results:
Mortality: -
PROM:
SF-36 (health-related
quality of life): Self-
reported CCI was
negatively associated with
PCS (b = –2.56, P , .001)
and MCS (b = –1.24, P =
.044). Medical record-
derived CCI scores had a
similar trend but
coefficients didn’t reach
statistical significance.
Healthcare utilization: -
Habbous25 Exposures
Smoking and alcohol
Conditions/Diseases
Chronic cough/bronchitis
Dementia (eg, Alzheimer’s)
Diabetes (eye/kidney problems)
(Past) Dialysis requirement
Emphysema
Heart failure
Hemiplegia
Hepatitis
HIV/AIDS
Liver disease
Myocardial infarction
Other joint/bone problems
Past cancer history
Peripheral vascular disease
Rheumatoid arthritis
Serious kidney problems
Stomach ulcers (test-proven)
Stroke/mini-stroke
882 head-and-neck cancer
patients.
Characteristics:
Female 23%
Median age 61.5 years (61-62.5)
Caucasian 84%
Comparison: Medical record-
derived CCI
Results:
Kappa: 0.16 (hemiplegia) – 0.93
(diabetes)
Sensitivity: -
Specificity: -
PPV: -
NPV: -
Positive agreement between
self-reported CCI and medical
record-derived CCI ranged from
17% (hemiplegia) to 94%
(diabetes). Negative agreement
between self-reported CCI and
medical record-derived CCI
ranged from 84 (CTD) to 100%
(dementia).
Comparison: Medical record-
derived CCI
Results:
Patient-reported CCI scores
were higher than the medical
record-derived CCI scores (mean
1.01 (95% CI 0.9-1.1) vs 0.74 (95%
CI 0.7-0.8), P , .0001).
Comorbidities were reported
more often by patients in
comparison to medical records
review.
Overall agreement between
patient-reported CCI and
medical record-derived CCI was
measured as k = 0.37, which
improved if CTD (k = 0.52) or
COPD (k = 0.43) was removed
from the patient-reported CCI
score.
Comparison: Medical
record-derived CCI
Results:
Mortality:
Overall survival: Both
patient-reported CCI (HR
1.62 (95% CI 1.18-2.24), P =
.003) and medical record-
derived CCI (HR 1.97 (95%
CI 1.38-2.80), P = .0002)
were significantly
associated with overall
survival after multivariate
(age, sex, marital status,
stage, and disease site)
adjustment, when at least
2 comorbidities were
present.
PROM: -
Healthcare utilization: -
continued on next page
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Table 2. Continued
Items Study population (n) Item-level reliability vs other
data sources
Overall instrument reliability
vs other data sources
Evaluated outcome(s)
Chaudhry26 Asthma/emphysema/ Chronic
bronchitis
Arthritis or rheumatism
Cancer (diagnosed within past 3
years)
Diabetes
Digestive problems (ie, ulcer/
colitis/gallbladder disease)
Heart trouble (ie, angina/ CHF/
CAD)
HIV or AIDS
Kidney disease
Liver problems (cirrhosis)
Stroke
7761 hospitalized general
medicine patients at a single
center.
Characteristics:
Female 62%
Mean age 56-57 years
African-American .80%
MMSE score . 17
Comparison: Administrative
data-derived CCI
Results:
Item-level data vs one-year look-
back:
Kappa: 0.04 (stomach ulcer) –
0.83 (diabetes)
Sensitivity: 44 (cancer) – 86%
(diabetes, HIV/ AIDS)
Specificity: 48 (arthritis or
rheumatism) – 98% (HIV/ AIDS)
PPV: 3 (stomach ulcers) – 90%
(diabetes)
NPV: 91 (asthma, emphysema,
or bronchitis) – 100% (HIV/ AIDS)
Item-level data vs index
hospitalization:
Kappa: 0.06 (arthritis or
rheumatism) – 0.82 (diabetes)
Sensitivity: 43 (cancer) – 91%
(diabetes)
Specificity: 47 (arthritis or
rheumatism) – 95% (liver
disease, cancer)
PPV: 9 (arthritis or rheumatism)
– 84% (diabetes)
NPV: 93 (asthma, emphysema or
bronchitis) – 99% (heart disease,
kidney disease, liver disease,
cancer)
No statistically significant
differences in Kappa values,
sensitivities, specificities,
or positive or negative predictive
values was observed for 1-year
look-back periods or index
hospitalization.
- The predictive power of the
self-reported CCI was
constructed with 4
different logistic regression
models performed in a
validation cohort (n =
3870).
Model 1: age, sex + original
CCI weight
Model 2: age, sex + study-
specific CCI weight
Model 3: age, sex,
diagnosis-related group
weight + original CCI
weight,
Model 4: age, sex,
diagnosis-related group
weight + study-specific CCI
weight
Results:
Mortality:
One-year mortality: AUCs
for the self-reported CCI
were 0.70 (0.68-0.73) for
model 1, 0.72 (0.70-0.75)
for model 2, 0.75 (0.72-
0.77) for model 3, and 0.76
(0.73-0.78) for model 4.
AUCs were slightly less
compared with the
administrative data-
derived CCI indices (P ,
.001).
PROM: -
Healthcare utilization:
Log total costs: R2 values
for the different regression
models ranged from 0.02
(models 1 & 2) – 0.33
(models 3 & 4)
Log length of stay: R2
values for the different
regression models ranged
from 0.01 (model 1) – 0.22
(models 3 & 4)
continued on next page
-- 9
Table 2. Continued
Items Study population (n) Item-level reliability vs other
data sources
Overall instrument reliability
vs other data sources
Evaluated outcome(s)
Sangha27 Anemia or other blood disease
Back pain
Cancer
Depression
Diabetes
Heart disease
High blood pressure
Kidney disease
Liver disease
Lung disease
Osteoarthritis/ Degenerative
arthritis
Other medical problems
(optional)
Rheumatoid arthritis
Ulcer or stomach disease
170 hospitalized patients from 6
care units at one hospital.
Characteristics:
Female 55%
Mean age 65.3 years (6 SD 8.8)
Caucasian 82%
College level or higher 50%
Comparison: Medical record-
derived CCI
Results:
Kappa: 0.27 (lung disease) – 0.93
(liver disease)
Sensitivity: -
Specificity: -
PPV: -
NPV: -
Overall agreement between the
SCQ and the medical record-
derived CCI ranged from 78%
(heart disease) to 99% (liver
disease).
Comparison: Medical record-
derived CCI
Results:
SCQ scores were higher than the
medical record-derived CCI
scores (mean 5.61 6 SD 4.1 vs
1.59 6 SD 2.13)
SCQ had a fair correlation
(Spearman r = 0.32) with the
medical record-derived CCI,
which slightly increased
(Spearman r = 0.55) when
questionnaires were truncated
to only comparable items.
Comparison: Medical
record-derived CCI
Results for medical
patients:
Mortality: -
PROM: -
SF-36 (health-related
quality of life): SCQ had
poor to modest
correlations with SF-36
(subscale) scores at one-
year follow-up, ranging
from “MCS” (Spearman r =
–0.03, P . .05) to “General
health” (Spearman r =
–0.39, P, .0001). Total SCQ
scores explained
substantial variation for
most SF-36 subscales, with
R2 values ranging from
0.10 (“Social function”) to
0.25 (“Physical function”) in
multivariate (including age,
sex, ethnicity, education
level, and insurance status)
linear regression models.
Healthcare utilization:
Hospitalizations in
previous year: SCQ scores
correlated fairly with
hospitalizations in the
previous 12 months
(Spearman r = 0.21, P , .01
for medical patients;
Spearman r = 0.37, P , .01
for surgical patients)
Prescription medication:
SCQ scores also correlated
moderately with number
of prescriptions (Spearman
r = 0.40 for medical
patients; r = 0.55 for
surgical patients)
Total hospital charges: SCQ
scores correlated poorly
with total inpatient charges
(Spearman r = 0.09 for
medical patients; r = 0.10
for surgical patients)
Length of stay: SCQ scores
also correlated poorly with
hospital length of stay
(Spearman r = 0.03 for
medical patients; r = 0.14
for surgical patients)
continued on next page
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Table 2. Continued
Items Study population (n) Item-level reliability vs other
data sources
Overall instrument reliability
vs other data sources
Evaluated outcome(s)
Stolwijk28 Dutch modified version (mSCQ)
of the SCQ instrument27
Anemia or other blood disease
Back pain
Cancer
Depression
Diabetes
Heart disease
High blood pressure
Kidney disease
Liver disease
Lung disease
Osteoarthritis
Other non-specified medical
problems (optional; max. 3)
Rheumatoid arthritis
Ulcer or stomach disease
98 outpatients with ankylosing
spondylitis. Data from the OASIS
study.29
Characteristics:
Female 29.6%
Mean age 53.9 years (6 SD 11.4)
College level or higher 15.7%
Comparison: Medical records
Results:
Kappa: 0.14 (osteoarthritis, ulcer
disease) – 1.00 (cancer). Kappa
analysis included 10 conditions.
Sensitivity: -
Specificity: -
PPV: -
NPV: -
Comparisons:
1. Medical record-derived CCI
2. Michaud-Wolfe index
Results:
SCQ had poor to fair correlations
with the medical record-derived
CCI (Spearman r = 0.24, P , .05)
and Michaud-Wolfe index
(Spearman r = 0.43, P , .05)
mSCQ also had moderate
correlations with CCI (Spearman
r = 0.36, P , .05) and Michaud-
Wolfe index (Spearman r = 0.57,
P , .05)
Comparisons:
1. Medical record-derived
CCI
2. Michaud-Wolfe index
Results:
Mortality: -
PROM:
BASDAI (disease activity):
SCQ correlated moderately
with disease activity
(Spearman r = 0.27, P ,
.05), while CCI correlated
poorly (Spearman r = 0.01).
SCQ was significantly
associated (OR = 1.73, 95%
CI 1.25-2.40, P , .01) with
low disease activity
(BASDAI , 4).
BASFI (physical function):
SCQ correlated moderately
(Spearman r = 0.43, P ,
.05) with physical function,
but was significantly
associated (b = 0.11, 95% CI
0.03-0.19, P = .01) with
BASFI.
SF-36 (health-related
quality of life): SCQ
correlated moderately
(Spearman r = -0.45, P ,
.05) with the PCS subscale,
and was significantly
associated (b = –0.72, P =
.03) with PCS.
CCI and Michaud-Wolfe
indices were not
significantly associated
with BASFI and SF-36-PCS.
Healthcare utilization: -
Robinski30 German version (SCQ-G) of the
SCQ instrument27
780 adult end-stage renal
disease patients from 55 dialysis
units. Data from the CORETH
project.31
Characteristics:
Female 32.6%
Mean age 63.2 years (6 SD 15.1)
Comparison: Medical record-
derived CCI
Results:
Kappa: 0.01 (peptic ulcer
disease) – 0.84 (diabetes)
Sensitivity: -
Specificity: -
PPV: -
NPV: -
Overall agreement between the
SCQ and CCI ranged from 70%
(heart disease) to 95% (kidney
disease, liver disease). Positive
agreement between both data
sources ranged from 6% (peptic
ulcer disease) to 97% (kidney
disease). Negative agreement
ranged from 78% (heart disease)
to 97% (liver disease).
Comparison: Medical record-
derived CCI
Results:
Total SCQ-G score was
moderately correlated to the
medical record-derived CCI
(Spearman r = 0.27, P , .01).
Comparison: Medical
record-derived CCI
Results: -
Mortality: -
PROM: -
SF-12 (health-related
quality of life): Total SCQ-G
score was moderately
correlated with MSC
(Spearman r = –0.25, P ,
.01) and PSC (Spearman r =
–0.49, P , .01) subscales,
while CCI correlated poorly
with MSC (Spearman r =
0.06, P . .05) and
moderately with PSC
(Spearman r = –0.36, P ,
.01).
Healthcare utilization: -
continued on next page
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Table 2. Continued
Items Study population (n) Item-level reliability vs other
data sources
Overall instrument reliability
vs other data sources
Evaluated outcome(s)
Bayliss32 Angina/ CAD
Asthma
Back pain (chronic) or sciatica
Bronchitis (chronic)/ COPD
Cancer (diagnosed within past 5
years)
Cholesterol (elevated)
Colon problem (eg, diverticulitis/
irritable bowel)
Congestive heart failure
Diabetes
Hard of hearing
Hypertension
Kidney disease
Nerve condition
Osteoarthritis
Osteoporosis
Overweight
Poor circulation (eg, peripheral
vascular disease)
Rheumatic disease (eg,
fibromyalgia or lupus)
Rheumatoid arthritis
Stomach problem (eg, gastritis/
ulcer/ reflux)
Stroke
Thyroid disorder
Vision problem
156 patients ($ 65 years) from
the HMO
Characteristics:
Female 49.4%
Mean age 75 years (67-94)
Caucasian 91%
College level or higher 59.6%
Comparison: Medical records
Results:
Kappa: -
Sensitivity: 35 (kidney disease) –
100% (asthma)
Specificity: 61 (hard of hearing) –
100% (kidney disease, cancer)
PPV: -
NPV: -
Comparison: Medical records
Results:
Sensitivity by respondent
analysis: 14%-100% (median
75%)
Specificity by respondent
analysis: 59%-100% (median
91%)
Comparisons:
1. Medical records
2. Medical record-derived
CCI
3. Rx-risk score
(comorbidity measure
including age, gender,
health insurance benefit
status, and a category
based on diagnoses from
administrative pharmacy
data)
Results:
Mortality: -
PROM:
SF-36 (health-related
quality of life): Self-
reported number of
conditions (Spearman r =
0.477, P , .001) had a
similar correlation
compared to the medical-
record CCI (r = 0.48, P ,
.001) but higher compared
to the Rx risk score (0.17, P
= .037).
SF-36 (physical
functioning): Self-reported
conditions (r = –0.482, P ,
.001) had a stronger
correlation vs CCI (r =
–0.41, P , .001) and the Rx
Risk score (r = –0.18, P =
.035).
BRFSS (depression
screening): Self-reported
conditions (r = –0.24, P =
.003) had a stronger
correlation compared with
CCI (r = –0.12, P = .14) and
the Rx Risk score (r = –0.05,
P = .559).
GSE (self-efficacy): Self-
reported conditions (r =
–0.305, P , .001) had a
stronger correlation vs CCI
(r = –0.14, P = .096) and the
Rx Risk score (r = 0.10, P =
.234).
Healthcare utilization: -
Poitras33 French modified version (DBMA-
Fv) of the DBMA instrument32:
21 of the 23 original conditions
were chosen.
Items “Kidney disease” and
“Nerve condition” were excluded
in this version
Item “Depression/ anxiety” was
added to this version
78 patients from 1 health center.
Characteristics:
Female 68%
Mean age 47.4 years (6 SD 15.9)
College level or higher 70.5%
Comparison: Medical records
Results:
Kappa: -
Sensitivity: 62.5 (angina/ CAD) –
90% (diabetes)
Specificity: 77.6 (overweight) –
98.6% (diabetes)
PPV: 44.4 (overweight) – 92.9%
(hypercholesterolemia)
NPV: 88.7 (osteoarthritis) –
95.9% (asthma/ diabetes)
Comparison: Cumulative Illness
Rating Scale
Results:
DBMA-Fv correlated moderately
with the CIRS at baseline (r =
0.46, 95% CI 0.26-0.62, P , .01)
and at 2 weeks’ follow-up
(Spearman r = 0.56, 95% CI 0.38-
0.70, P , .01).
Comparison: Medical records
Results:
Mean sensitivity of patient-
reported conditions vs medical
record review at 2 weeks was
73.9% (6 SD 8.4), whereas mean
specificity was 92.2% (6 SD 6.7).
-
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Table 2. Continued
Items Study population (n) Item-level reliability vs other
data sources
Overall instrument reliability
vs other data sources
Evaluated outcome(s)
Wijers34 Spanish modified version of the
DBMA instrument32:
21 out of the 23 original
conditions were chosen
Item “Liver disease” was
excluded from this version due
to low prevalence
Items “UTI,” “anxiety” and
“memory-related disorders”
were added to this version due
to high prevalence in older
adults
707 community-dwelling adults
($65 years). Data from the ELES-
PS study.35
Characteristics:
Female 57%
Mean age 74.2 years (6 6.6)
College level or higher 17.3%
- - Comparison: Self-reported
conditions
Results: -
Mortality: -
PROM: -
PWI (physical functioning &
perceived health status):
DBMA significantly
correlated stronger to
physical functioning than
self-reported number of
conditions (Spearman r =
–0.56 vs r = –0.51, P =
.0035)
PWI (quality of life): DBMA
significantly correlated
stronger to PWI in
comparison to self-
reported number of
conditions (Spearman r =
–0.41 vs r = –0.35, P =
.0006)
CES-D (depression
screening): DBMA
significantly correlated
stronger to CES-D
compared to self-reported
number of conditions
(Spearman r = 0.41 vs r =
0.35, P = .0043)
Healthcare utilization: -
Simpson36 Angina pectoris
Arthritis (OA/RA)
Cancer
Congestive heart failure
Diabetes mellitus
Disc disease
Hip fracture
Lung disease
Myocardial infarction
Osteoporosis
Parkinson’s disease
Peripheral arterial disease
Spinal stenosis
Stroke
1002 disabled women, aged$65
years, with MMSE $18. Data
from the Women’s Health and
Aging Study I.37
Characteristics:
Age group 65-74 years 44.2%
Caucasian 71.1%
Comparison: Disease-specific
standardized algorithms
(medical history, physical
examination, medication review,
medical record review,
radiographs, physician
questionnaire)
Results:
Kappa: 0.24 (peripheral arterial
disease) – 0.96 (hip fracture)
Sensitivity: 22 (spinal stenosis) –
98% (stroke)
Specificity: 45 (arthritis) – 100%
(hip fracture, Parkinson’s
disease, disc disease, spinal
stenosis)
PPV: 0.20 (peripheral arterial
disease) – 1.0 (Parkinson’s
disease)
NPV: 0.38 (arthritis) – 1.0 (hip
fracture, Parkinson’s disease,
cancer, stroke)
- -
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Items Study population (n) Item-level reliability vs other
data sources
Overall instrument reliability
vs other data sources
Evaluated outcome(s)
Crabtree38 Angina
Anxiety and depression
Any other condition
Arthritis/osteoporosis
Breathlessness secondary to
cardiovascular cause
Breathlessness/ Wheeze
(secondary to respiratory cause)
Cerebrovascular disease
Constipation
Cough/Sputum (secondary to
COPD/ Asthma)
Diabetes
Diarrhea
Epilepsy
Hearing problems
Pain
Parkinson’s disease
Peripheral vascular disease
Side effects from medications
Skin disease
Unsteadiness, falls, and syncope
Upper gastrointestinal
symptoms
Urinary problems
Visual problems
Walking and mobility
183 patients $ 65 years with
confirmed age-related cataract
(n = 161) or from a geriatric day
hospital (n = 22)
- - Comparison: -
Results:
Mortality: -
PROM: -
NEADL (activities of daily
living): CmSS correlated
moderately to the NEADL
(Spearman r = 0.56, P ,
.01).
GHQ-28 (perceived health
status): CmSS correlated
poorly to the GHQ-28
(Spearman r = 0.48, P ,
.01)
HAD (anxiety and
depression): CmSS
correlated moderately to
the HAD (Spearman r =
0.52, P , .01).
Healthcare utilization: -
De-loyde39 Another cancer
Chronic respiratory disease
Depression
Diabetes
Heart disease
Hypertension
Kidney disease
756 patients with colorectal
cancer from multiple hospitals.
Data from the CONNECT40 RCT.
Characteristics:
Female 56%
Age group ,70 years 54%
College level or higher 24%
Comparison: Clinician report
Results:
Kappa: 0.22 (another cancer) –
0.58 (diabetes)
Sensitivity: -
Specificity: -
PPV: -
NPV: -
Comparison: Medical records
Results:
Kappa: 0.34 (kidney disease) –
0.77 (diabetes)
Sensitivity: -
Specificity: -
PPV: -
NPV: -
- -
Gad41 Amputation
Anemia or other blood problems
Asthma/ Other lung disease
Back pain
Blood clots or phlebitis
Bowel problems
Cancer
Chronic skin condition
Congestive heart failure
Depression or anxiety
Diabetes
Excessive weight
Hearing loss
Heart attack
High blood pressure
High cholesterol
Kidney or urinary problems
Liver/ Gallbladder disease
Lupus/ Other autoimmune
disease
Neuromuscular disease
Osteoarthritis/ Degenerative
arthritis
Osteoporosis
Paralysis
Peripheral vascular disease
Previous fracture(s)
Recent unwanted weight loss
Rheumatoid arthritis
Sleep problems
Stroke
Thyroid problems
Ulcer/stomach problems
Visual problems
382 preoperative orthopedic
patients (aged $ 65 years)
before undergoing total knee or
hip arthroplasty
Characteristics:
Female 65%
Mean age 74 years (6 SD 6.1)
Comparison: Medical records
Results:
Kappa: 0.00 (osteoarthritis) –
0.76 (diabetes)
Sensitivity: 9 (peripheral vascular
disease) – 71% (hypertension)
Specificity: 44 (osteoarthritis) –
99% (diabetes)
PPV: -
NPV: -
- -
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Table 2. Continued
Items Study population (n) Item-level reliability vs other
data sources
Overall instrument reliability
vs other data sources
Evaluated outcome(s)
Hansen42 For analysis (32 of 46 diagnosis
groups):
Anemia
Asthma/ COPD
Atherosclerosis/ PAOD
Cancers
Cardiac arrhythmias
Cardiac insufficiency
Cardiac valve disorders
Cerebral ischemia/ Chronic
stroke
Chronic cholecystitis/ Gallstones
Chronic ischemic heart disease
Chronic low back pain
Diabetes mellitus
Dizziness
Gynecological problems
Hemorrhoids
Hypertension
Hyperuricemia/gout
Intestinal diverticulosis
Joint arthrosis
Lipid metabolism disorders
Lower limb varicosis
Migraine/chronic headache
Neuropathies
Osteoporosis
Parkinson disease
Prostatic hyperplasia
Psoriasis
Renal insufficiency
Rheumatoid arthritis/ chronic
polyarthritis
Severe vision reduction
Thyroid dysfunction
Urinary tract calculi
3189 multimorbid primary care
patients. Data from the Multi-
Care Cohort Study.43
Characteristics:
Female 59.3%
Mean age 74.4 years (6 SD 5.2)
College level or higher 10.9%
Comparison: Clinician report
Results:
Kappa: 0.05 (gynecological
problems) – 0.80 (diabetes)
Sensitivity: -
Specificity: -
PPV: -
NPV: -
- -
Horton44 Anemia
Anxiety
Arthritis
Bipolar disorder
Breast cancer
Cataracts
Colon cancer
Depression
Diabetes
Epilepsy
Fibromyalgia
Glaucoma
Heart disease
Hip replacement
Hyperlipidemia
Hypertension
Inflammatory bowel disease
Irritable bowel syndrome
Kidney disease
Knee replacement
Liver disease
Lung cancer
Lung disease
Migraine
Osteoporosis
Peptic ulcer disease
Peripheral vascular disease
Rectal cancer
Rheumatoid arthritis
Schizophrenia
Sjogren’s syndrome
Skin cancer
Systemic lupus erythematosus
Thyroid
Uveitis
Vitamin-B12 deficiency
404 patients with multiple
sclerosis from 2 centers.
Characteristics:
Female 76%
Mean age 46.5 years (6 SD 11.8)
Caucasian 92%
College level or higher 63.4%
Relapsing-remitting MS 70.8%
Comparison: Medical records
Results:
Kappa: 0.19 (anemia) – 0.88
(diabetes)
Sensitivity: 14 (kidney disease) –
100% (bipolar disorder, breast
cancer, glaucoma, lung cancer,
rheumatoid arthritis,
schizophrenia, cataracts)
Specificity: 87 (depression) –
100% (breast cancer, lung
cancer)
PPV: 0.07 (skin cancer) – 1.00
(breast cancer/ lung cancer)
NPV: 0.84 (depression) – 1.00
(bipolar disorder, breast cancer,
cataracts, glaucoma, lung
cancer, rheumatoid arthritis,
schizophrenia)
Comparison: Medical records
Results:
Agreement between self-reports
and medical records was k =
0.56 (95% CI 0.48-0.64) for the
presence of any physical
comorbidity, and k = 0.57 (95%
CI 0.48-0.65) for mental
comorbidities. For this analysis,
the questionnaire was divided
into physical vs mental
comorbid conditions, and
thereafter dichotomized in 0 vs
.0 comorbidities.
-
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Items Study population (n) Item-level reliability vs other
data sources
Overall instrument reliability
vs other data sources
Evaluated outcome(s)
Iecovich45 Arthritis
Cancer
Cardiovascular accident
Circulatory disease
Diabetes
Gastrointestinal disease
Hypertension
Myocardial infarction
Osteoporosis
Other heart diseases
Renal problems
Respiratory disease
Thyroid disease
402 disabled older patients who
used adult daycare centers.
Characteristics:
Female 74.8%
Mean age 78 years (6 SD 7.02)
Asian/ African 62.6%
College level or higher 10.1%
Comparison: Medical records
(including diagnostic ICD-9
codes)
Results:
Kappa: 0.09 (circulatory disease)
– 0.76 (diabetes)
Sensitivity: 22.5 (cancer) - 79.1%
(diabetes)
- Specificity: 73.5 (renal) – 98%
(cancer)
PPV: 0.36 (circulatory disease) –
0.92 (hypertension)
NPV: 0.42 (hypertension) – 0.87
(thyroid disorder)
Comparison: Medical records
(including diagnostic ICD-9
codes)
Results:
Self-reports correlated fairly
with the EHR (r = 0.45, P , .001).
-
Klabunde5 Angina
Arthritis or rheumatism
Chronic Lung Disease/
Bronchitis/emphysema
Cirrhosis/liver disease
Congestive heart failure
Depression or anxiety
Diabetes
Hypertension
IBD/colitis/Crohn disease
Myocardial infarction
Stroke/brain hemorrhage
Stomach ulcers with bleeding
3095 prostate cancer survivors.
Data from the PCOS study.46
Characteristics:
Age group .65 years 64%
Caucasian 78%
College level or higher 60%
- - -
Boissonnault47 Anemia
Ankylosing spondylitis
Arterial blockage of legs
Asthma
Cancer
Chemical dependency
Deep venous thrombosis
Degenerative osteoarthritis or
wear-and-tear arthritis
Depression
Diabetes (diagnosed after age 18
years)
Diabetes (diagnosed before age
18 years)
Emphysema
Endometriosis
Epilepsy/seizures
Gout
Headaches (.1 per week)
Heart attack
Heart valve problems
Hepatitis
Hypertension
Hyperthyroid
Hypothyroid
Infections
Multiple sclerosis
Osteoporosis
Other illnesses (please list)
Rheumatoid arthritis
Stomach/duodenal ulcers
Stroke
Tuberculosis
Urinary incontinence
Questionnaire contains 91 items
divided into 8 sections
(comorbidities, surgeries,
medication, substance use and
demographic characteristics)
100 preoperative orthopedic
surgery patients at 1 hospital.
Characteristics:
Female 54%
Mean age 46.9 years (6 SD 16.7)
College level or higher 64%
Comparison: NP/PA responses
to identical questionnaire after
medical record review and/or
patient interview
Results:
Kappa: 0.15 (other illnesses) –
1.00; mean k = 0.69
Sensitivity: -
Specificity: -
PPV: -
NPV: -
Comparison: NP/PA responses
to identical questionnaire after
medical record review and/or
patient interview
Results:
Mean percentage agreement
across all questionnaire items
between self-report and NP/PA
report was 96%.
-
continued on next page
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Table 2. Continued
Items Study population (n) Item-level reliability vs other
data sources
Overall instrument reliability
vs other data sources
Evaluated outcome(s)
Fan48 Angina
Arthritis
CABG/PTCA
Cancer
Congestive heart failure
Coronary artery disease
Depression
Diabetes
Drug abuse
Enlarged prostate
Heartburn
HIV
Hypertension
Liver disease
Lung disease
Osteoporosis
Pneumonia
Post-Traumatic Stress Disorder
Prior myocardial infarction
Renal insufficiency
Seizure
Stroke
Thyroid disease
Ulcer disease
Development sample: 5469
patients from 7 VA medical
centers. Data from the ACQUIP49
study.
Characteristics:
Female 2.5%
Mean age 67.8 years (6 SD 0.1)
Caucasian 83.4%
College level or higher 68.7%
Validation sample: 5478 patients
from 7 VA medical centers
Characteristics:
Female 2.7%
Mean age 67.8 years (6 SD 0.1)
Caucasian 83.3%
College level or higher 68%
- - Comparison: -
Results: -
Mortality: -
All-cause mortality: SIC had
a moderate discriminative
ability (AUC = 0.71) of SIC in
predicting mortality at 2
years’ follow-up. A
combined model,
containing SIC and SF-36 as
predictors, had an AUC =
0.74.
PROM: -
Healthcare utilization:
Re-hospitalizations:
Discriminative ability of SIC
was less able in predicting
2-year re-hospitalizations
(AUC = 0.61), which slightly
increased when SF-36 was
added to the model (AUC =
0.64).
Lorem50 All respondents:
Angina
Asthma
Atopic eczema
Cancer survivor
Cerebrovascular stroke
Chronic bronchitis
Diabetes
Duodenal ulcer
Epilepsy
Fibromyalgia
Food allergies
Hand eczema
Hypersensitivity
Kidney stone
Liver disease
Migraine
Myocardial infarction
Osteoporosis
Pollen allergies
Psoriasis
Thyroid
Ventricular ulcer
For patients .70 years, added:
Arthritis
Cataract
Glaucoma
Parkinson disease
Rheumatoid arthritis
Urinary incontinence
Reference population: 26 684
patients sampled from Tromsø
study (1994/
1995).51
Characteristics:
Female 52.6%
Age group ,50 years 61.7%
Validation population: 804
patients sampled from Tromsø
study and FHI panel (2001/2002).
Characteristics:
Female 55%
Ages 30-79 years
- Comparison: Medical record-
derived CCI
Results:
HII correlated more strongly
with SRH vs CCI (Spearman r =
–0.360, P , .001 vs r = –0.250, P
, .001). After excluding all
patients with HII = 0, the
correlation between HII and SRH
strengthened (r = –0.421, P ,
.001) as it weakened between
CCI and SRH (r = –0.141, P ,
.001).
Comparison: -
Results:
Mortality: -
PROM:
SRH: In an ordinal logistic
regression model
(containing age, gender,
mental health symptoms
and the HII), HII had a
negative effect (b = –0.249,
P , .001) after adjustment
for the other variables.
Healthcare utilization: -
Lucke52 For analysis:
Asthma
Cardiovascular disorder
(combined)
Coronary heart disease
Diabetes mellitus
Dyslipidemia
GI
Hypertension
Hyperuricemia
Mental disorders
Osteoporosis
Original questionnaire
comprised of 51 (combined)
diseases, as well as free text.
2653 patients with COPD or
chronic bronchitis. Data from
the COSYCONET53 study.
Characteristics:
Male 59.4%
Mean age 65 years (6 SD 8.6)
Mean BMI 27 (6 SD 5.4)
GOLD # 2 57.7%
Comparison: ATC-codes for
disease-specific medication
Results:
Concordance between self-
reported comorbidities and ATC
codes for disease-specific
medication varied from 1.3%
(asthma) to 51.8% (combined
CVD).
Comparison: Matched ICD-10
codes for diseases and
nonspecific medications
Results:
About 51.5% of self-reported
comorbidities were confirmed
after comparing them with
matched ICD-10 codes.
-
continued on next page
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Table 2. Continued
Items Study population (n) Item-level reliability vs other
data sources
Overall instrument reliability
vs other data sources
Evaluated outcome(s)
Md Yusof54 18 sections:
12 physical systems
6 mental health state
an additional free text option for
medication prescription.
113 community-dwelling
patients from 1 research center.
Characteristics:
Female 56.6%
Mean age 75.3 years (6 SD 5.19)
- Comparison: Clinician report
Results:
CMI correlated significantly with
the GP-data (r = 0.8, P,.001).
Comparison: -
Results:
Mortality:
Survival: In a Cox
proportional hazards
model containing 5
continuous predictors (age,
weighted CCI, combined
condition and age-related
CCI score, total score
physical sections of CMI,
total score mental sections
of CMI, and count of
medication prescriptions),
none of these predictors
significantly contributed to
predicting mortality.
PROM: -
Healthcare utilization: -
Merkin55 Angioplasty or CABG
Cancer
Cerebrovascular disease
CHF
COPD
Diabetes
Hypertension
Myocardial infarction
965 patients with ESRD from 81
dialysis clinics. Data from the
CHOICE study.56
Characteristics:
Female 46%
Mean age 58 years
Caucasian 67%
College level or higher 36%
Comparison: Medical record-
derived ICED
Results:
Kappa 0.19 (hypertension) – 0.93
(diabetes)
Sensitivity: 18 (COPD) – 96%
(diabetes)
Specificity: 76 (hypertension) –
98% (diabetes)
PPV: -
NPV: -
Comparison: Clinician report
Results:
Kappa 0.19 (hypertension) – 0.81
(diabetes)
Sensitivity: -
Specificity: -
PPV: -
NPV: -
- -
Mukerji57 Arthritis
Diabetes
Heart disease
Lung disease
Other cancers (apart from index
tumor)
Psychiatric problems
Stroke
458 patients with newly
diagnosed head-and-neck
cancer from 3 hospitals.
Characteristics:
Female 23.6%
Caucasian 86%
College level or higher 49.8%
Comparison: Medical record-
derived ACE-27 index
Results:
Kappa: 0.11 (arthritis) – 0.89
(diabetes)
Sensitivity: -
Specificity: -
PPV: -
NPV: -
Overreporting by self-report
occurred more often (21.2%)
compared with underreporting
(13.5%), with medical records as
gold standard.
Comparison: Medical record-
derived ACE-27 index
Results:
Kappa: 0.50 (0.44 – 0.57)
-
Paleri58 9 section headers: Heart & blood
vessels
Alcohol consumption
Brain and nerves
Cancer
Diabetes
Joints and muscles
Kidney
Liver, stomach, and pancreas
Lungs
20 patients with head-and-neck
cancer.
Characteristics: -
- Comparison: Medical record-
derived ACE-27 grade
Results:
Kappa: 0.92 (95% CI 0.82-1.0)
-
continued on next page
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Table 2. Continued
Items Study population (n) Item-level reliability vs other
data sources
Overall instrument reliability
vs other data sources
Evaluated outcome(s)
Pati59 Acid peptic disease
Arthritis
Asthma
Cancer
Chronic back ache
Chronic kidney disease
Chronic liver disease (alcohol)
Deafness
Dementia
Diabetes
Epilepsy
Filariasis
Heart disease
Hypertension
Stroke
Thyroid
Tuberculosis
Visual difficulty
103 patients from 4 primary care
practices.
Characteristics:
Female 45%
Mean age 45 years (6 SD 5.32)
Comparison: Clinician’s
prescription-derived data
Results:
Kappa: 0.58 (hearing problem) –
1.00 (tuberculosis); 16 of 18
conditions were evaluated.
Sensitivity: -
Specificity: -
PPV: -
NPV: -
- -
Lee60 Alcohol use
Arthritis
BMI , 25
Chronic lung disease
Current tobacco use
Diabetes mellitus
Heart failure
History of falls
History of pain
Hypertension
Incontinence
Memory-related disease
Non-skin cancers
Other heart problems
Psychiatric disease
Stroke
Visual or hearing impairment
Older (.50 years) community-
dwelling patients. Data from the
Health and Retirement
Study.61,62
Development cohort: 11 701
patients
Characteristics:
Female 57%
Mean age 67 years (6 SD 10)
Caucasian 81%
High school level or higher 75%
Validation Cohort: 8009 patients
Characteristics:
Female 56%
Mean age 67 years (6 SD 10)
Caucasian 71%
High school level or higher 66%
- - Results:
- Mortality:
All-cause mortality: a final
model, predicting 4-year
mortality, included 12
variables (6 comorbid
conditions, sex, age, and 4
functional status
measures). Discriminative
ability of the model was
determined in the
development (ROC = 0.84)
and validation cohort (ROC
= 0.82).
- PROM: -
- Healthcare utilization: -
Voaklander63 Asthma
Cancer
Chronic back pain
Circulatory problems
Diabetes
Digestive problems
Emphysema
Epilepsy
Eye problems
Hay fever/allergies
Heart disease
Hypertension
Kidney disease
Liver disease
Other
Stomach ulcers
Stroke
Thyroid problems
518 patients receiving major
joint arthroplasty at 2 acute care
facilities (1995-1997)
283 patients receiving TKA.
Characteristics:
Female 59%
Mean age 69 years (6 SD 9)
235 patients receiving THA.
Characteristics:
Female 60%
Mean age 67.1 years (6 SD 12)
- Comparisons:
1. Medical record-derived CCI
2. Administrative data-derived
CCI
3. ICD-9 Sum of comorbidities
(available in the EHR)
Comparisons:
1. Medical record-derived
CCI
2. Administrative data-
derived CCI
3. ICD-9 Sum of
comorbidities
Results:
SRC correlated significantly with
the medical record-derived CCI
(Spearman r = 0.40, P , .01),
administrative data-derived CCI
(Spearman r = 0.32, P , .01) and
ICD-9 Sum (Spearman r = 0.39, P
, .01).
Results:
Mortality: -
PROM:
SF-36 & WOMAC (health-
related quality of life): SRC
explained similar amounts
in HRQoL domains
compared to the ICD-9
Sum, medical record-
derived CCI and
administrative data-
derived CCI.
Healthcare utilization:
Hospital stay: SRC
explained the variance in
acute length of stay less
better compared to the
other comorbidity
measures.
ER visits: SRC was slightly
better in predicting
emergency department
visits than the other
measures (2% variance).
continued on next page
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Items Study population (n) Item-level reliability vs other
data sources
Overall instrument reliability
vs other data sources
Evaluated outcome(s)
Selim64 Physical conditions:
Angina pectoris
Cancer
Cataract
Chronic low back pain
Chronic lung disease
Congestive heart failure
Diabetes
Diverticulitis
Enlarged prostate
Gallbladder disease
Gout
Heart attack
Hepatitis
High blood pressure
Inflammatory bowel disease
Irregular heartbeat
Osteoarthritis
Osteoporosis
Peptic ulcer
Peripheral vascular disease
Phlebitis
Prostatitis
Renal failure
Rheumatoid arthritis
Seizure
Skin cancer
Stroke
Thyroid disease
Transient ischemic attacks
Urinary tract infection
Mental conditions:
Alcohol use
Anxiety
Bipolar disorder
Depression
Posttraumatic stress disorder
Schizophrenia
2425 patients who previously
received ambulatory care. Data
from Veterans Health Study.
Characteristics:
Female 0%
Mean age 64 years (6 SD 12.7)
High school level or higher 41%
- - Comparison: -
Results:
Mortality:
Survival: In a Cox
proportional hazards
model, the mortality risk
was 14% for every
increment in physical CI
which decreased to 9% (P
, .05) after adjustment for
sociodemographic and
disability rating.
PROM:
SF-36 (health-related
quality of life):
Physical CI had the
strongest correlations
(Pearson’s r $ 0.29) with
SF-36-PCS, while the
mental CI correlated better
with SF-36-MCS (Pearson’s
r $ 0.30). Both physical
and mental CIs were
significantly correlated
with all SF-36 scales.
Combined physical/mental
CI also correlated
significantly with all HRQoL
scales (Pearson’s r range
–0.29 to –0.45).
Healthcare utilization:
Hospital visits: Both
physical and mental CIs
had significant coefficients
and explained 5% of the
variance in total outpatient
clinic visits, which
increased to 7% after
adjustment for
sociodemographic and
disability rating.
Vigen65 Arthritis
Cardiovascular disease
Diabetes
Gall bladder disease
High cholesterol
Hypertension
Intestinal polyps
Irritable bowel syndrome
Osteoporosis
Other cancers
Thyroid disorders
1936 breast cancer patients.
Data from the SFBCS66 & LACE67
studies.
Characteristics:
Mean age 60.4 years (6 SD 11.0)
Caucasian 71%
College level or higher 67.8%
Comparison: Medical records
(including diagnostic ICD-9
codes)
Results:
Kappa: 0.50 (other heart
diseases) – 0.87 (diabetes)
Sensitivity: 48 (other heart
diseases) – 90.5% (myocardial
infarction)
Specificity: 96 (other heart
diseases) – 99.5% (diabetes)
PPV: -
NPV: -
- Comparison: Medical
records (including
diagnostic ICD-9 codes)
Results:
Mortality:
All-cause mortality: No
significant differences in
HRs for covariates between
comorbidity models with
self-report vs medical
records as data source
(diabetes HR 1.65 vs 1.44;
hypertension 1.22 vs 1.55;
myocardial infarction 1.40
vs 1.73; other heart
diseases 1.07 vs 1.51) were
observed.
PROM: -
Healthcare utilization: -
- indicates unknown or not described in study
ACE-27 indicates Adult Comorbidity Evaluation – 27; ADL, Activities of Daily Living Scale; ACQUIP, Ambulatory Care Quality Improvement Project; AIDS, acquired
immunodeficiency syndrome; ASI, Activity Status Index; ATC, Anatomical Therapeutic Chemical code; AUC, area under the curve; BASDAI, Bath Ankylosing
Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BMI, body mass index; BRFSS, Behavior Risk Factor Surveillance System;
CABG, coronary artery bypass graft; CAD, coronary artery disease; CCI, Charlson Comorbidity Index; CES-D, Center for Epidemiologic Studies Depression Scale; CHF,
congestive heart failure; CHOICE, Choices for Healthy Outcomes in Caring for End-stage renal disease study; CI, confidence interval; CIRS, Cumulative Illness Rating
Scale; CMI, Cornell Medical Index; CmSS, Comorbidity Symptom scale; CONNECT, Centralized Nurse-Led Telephone-Based Care Coordination to Improve Outcomes
After Surgical Resection for Colorectal Cancer; COPD, chronic obstructive pulmonary disease; CORETH, the Choice of Renal Replacement Therapy project;
COSYCONET, COPD and Systemic Consequences – Comorbidities Network Cohort Study; CTD, connective tissue disease; CVA, cerebrovascular accident; CVD,
cardiovascular disorder; DBMA, Disease Burden Morbidity Assessment; DMBA-Fv, French version of the Disease Burden Morbidity Assessment; EHR, electronic
health record; ELES-PS, Aging in Spain Longitudinal study, Pilot Survey; EQ-5D, EuroQol-5 Dimension; ER, emergency room; ESRD, end-stage renal disease; FHI,
Norwegian Institute of Public Health; GHQ-28, General Health Questionnaire – 28; GOLD, Global Initiative for Chronic Obstructive Lung Disease; GP, general
practitioner; GSE, general self-efficacy; HAD, Hospital Anxiety and Depression Scale; HII, Health Impact Index; HIV, human immunodeficiency virus; HMO, Health
Maintenance Organization; HR, hazard ratio; HRQol, health-related quality-of-life; IBD, inflammatory bowel disease; ICC, intraclass correlation coefficient; ICD-9,
International Classification of Diseases version 9; ICD-10, International Classification of Diseases version 10; ICED, Index of Coexistent Disease; LACE, Life After
Cancer Epidemiology study; MCS, mental component summary; MMSE, Mini Mental Status Examination; MS, multiple sclerosis; MSC, mental sum scale; mSCQ,
modified version of the Self-Administered Comorbidity Questionnaire; NEADL, Nottingham Extended Activities of Daily Living; NP, nurse practitioner; NPV, negative
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predictive value; OA, osteoarthritis; OASIS, Outcome in Ankylosing Spondylitis International Study; OR, odds ratio; PA, physician assistant; PAOD, peripheral arterial
occlusive disease; PCOS, Prostate Cancer Outcomes Study; PID, pelvic inflammatory disease; PPV, positive predictive value; PROM, patient-reported outcome
measure; PSC, physical sum scale; PTCA, percutaneous transluminal coronary angioplasty; PWI, personal wellbeing index; r, Spearman correlation coefficient; RA,
rheumatoid arthritis; RCT, randomized controlled trial; ROC, receiver-operating characteristic; Rx, prescription; SCQ, Self-Administered Comorbidity Questionnaire;
SCQ-G, German version of the Self-Administered Comorbidity Questionnaire; SD, standard deviation; SF-36-MCS, Short-Form 36 Mental Component Summary scale;
SF-36-PCS, Short-Form 36 Physical Component Summary scale; SFBCS, San Francisco Bay Area Cancer Study; SIC, Seattle Index of Co-morbidity; SRC, Self-Reported
Co-Morbidity; SRH, Self-Reported Health; THA, total hip arthroplasty; TIA, transient ischemic attack; TKA, total knee arthroplasty; UTI, urinary tract infection; VA,
Veterans Affairs; WOMAC, Western Ontario McMaster Osteoarthritis Index; b = beta.
Table 2. Continued
-- 21age, 6 comorbidities, and 4 functional measures) for all-cause
mortality at 4 years follow-up.
The most common patient-reported outcome measure evalu-
ated with patient-reported morbidity instruments was the 36-item
Short Form Health Survey (SF-36).24,27,28,32,63,64 One study reported
a higher patient-reported CCI score being negatively associated
with SF-36 scores,24 and another reported the number of self-
reported conditions in the DBMA instrument being significantly
correlated to the SF-36 similar to the medical record–derived CCI.32
Selim et al64 also demonstrated a negative association between
high CI scores and SF-36 scores. Because of heterogeneous reports
on the association and correlation units between both measures in
the included studies, there was no clear consistency observed in the
direction of the association or correlation.
Several studies also analyzed the relationship between patient-
reported comorbidity instruments and healthcare utilization
outcomes (eg, [re]hospitalizations, emergency room visits, medi-
cal costs).9,11,26,27,63 Susser et al9 estimated an AUC of 0.68 and AUC
of 0.67 in predicting the number of hospital days and emergency
room visits, respectively. Katz et al11 estimated weak correlations
between the patient-reported comorbidity CCI and healthcare
utilization outcomes, and Sangha et al27 reported similar weak
associations with the SCQ.
Impact of Demographic Factors on Survey Validity and
Reliability
Thirteen studies reported associations between certain patient
characteristics and concordance of comorbidity questionnaires with
other sources of comorbidity data. Most studies reported higher age
beingsignificantlyassociatedwith loweragreementbetweenpatient-
reported and medical-record derived comorbidity
data.22,25,36,39,42,45,47,55,57 Nevertheless, Katz et al,11 Vigen et al,65 and
Horton et al did not observe a significant association. In terms of
reliability, Klabunde et al5 found a significant association between age
$ 65 years and inconsistent response patterns between baseline and
subsequent surveys. Higher concordance between patient-reported
and other comorbidity data sources was also associated with higher
education levels.11,39,42,45This associationwasalsoobserved forhigher
socioeconomic status.5 In contrast, Vigen et al65 only reported this
association for myocardial infarction. Simpson et al36 reported that
education level did not impact reliability, with Kappa values remain-
ing unaltered after adjustment. Some studies42,45,55 also reported
concordance being significantly influenced by sex, whereas others44
did not observe a significant observation.Discussion
Risk adjustment for benchmarking of healthcare outcomes
across multiple hospitals is dependent on accurate reporting of
case-mix factors such as patient morbidity (ie, comorbid condi-
tions). Clinicians have increasingly considered patient-reported
comorbidity instruments as a potential alternative to the labo-
rious review of medical and administrative records or as a methodto standardize the collection of data for important conditions
across hospitals. Previously published research has looked at
multimorbidity measures in primary care or community popula-
tion settings68 but, to our knowledge, this is the first systematic
literature review focusing on the development or subsequent
validation of general patient-reported morbidity instruments
(either indices or ad hoc lists of conditions).
Ten original patient-reported comorbidity instruments were
found, as well as additional variations on these original studies. The
most frequently cited instruments were the SR-CCI and the SCQ,
with the SR-CCI demonstrating stronger item-level reliability, overall
reliability, and overall agreement, but similar correlations with
healthcare utilization parameters. The number of items varied sub-
stantially from instrument to instrument. Most studies evaluated the
accuracy of self-reported comorbid conditions for individual items
compared with another data source, most commonly medical re-
cords review. Agreement with the medical record, which was
generally used as the gold standard, varied substantially based on
the comorbid condition listed within all of the reviewed survey in-
struments. The kappa values regarding item-level validity were
generally not used to eliminate questions with low reliability, lead-
ing to large intra-instrument variability. This variation by comorbid
condition was thought by the authors to be the result of accurate
medical record data with missed diagnoses by the patient and ac-
curate reporting by the patient with missed data in the medical
record. The authors postulated that disease items with low reliability
included diseases that are “resolved” (in the past),65 those that are
controlled with treatment (eg, hypertension),65 those without
symptoms,36 those with complex diagnostic criteria or ambiguous
disease categories (eg, heart diseases such as atherosclerosis or heart
failure),24,65 and those with confusing or overlapping names (eg,
arthritis vs osteoarthritis vs rheumatoid arthritis).24,36,44,57 Violán
et al69 demonstrated similar results in a cross-sectional study
comparing morbidity prevalence between electronic health records
and health surveys; self-reported morbidity prevalence was higher
among younger patients and for symptomatic conditions. Diseases
with clear definitions (eg, diabetes) and that required ongoing
treatment had higher agreement with other data sources and were
most accurately reported by patients.25,36,45 Even in those cases,
there may have been disagreement, such as if people with pre-dia-
betes classified themselves as diabetic or people with non–insulin-
dependent diabetes considered themselves not diabetic. Agreement
between patient-reported morbidity instruments and administrative
data was usually poor, with the limitation generally listed in some
studies that administrative data may underreport the presence of
comorbid conditions (“undercoding”) more than the medical record.
This systematic review highlights the lack of information on
the predictive validity of comorbidity data; a subset of included
studies examined the predictive capabilities of the patient-
reported comorbidity questionnaires/indices for outcomes such
as mortality, patient-reported outcome measures (such as func-
tional status or general health-related quality of life), and
healthcare utilization and costs. The patterns of correlations be-
tween patient-reported comorbidity data and mortality were as
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associated with poorer overall survival.25 The predictive ability of
patient-reported comorbidity indices were moderate to good
(AUCs . 0.70) for all-cause mortality, regardless of whether only
comorbidities were used or other variables were added to the
model.26,48,60 Unsurprisingly, higher patient-reported comorbidity
scores were significantly correlated and associated with lower
health-related quality of life scores (as measured by the SF-
36).24,27,28,32,63,64 Patient-reported comorbidity scores had low
positive (Spearmans r , 0.50) correlations with many healthcare
utilization measures (eg, hospitalizations, length of hospital stay,
prescribed medications)11,27 and had poor discriminative ability
(AUCs between 0.60-0.70) for these measures as well.9,48 Because
comorbidity measures can influence outcomes and interpretation
when comparing treatment strategies or hospitals, it is essential
that a comorbidity measure is validated for the population and
outcome of interest.
Gold standard survey instrument development generally be-
gins with a systematic exploration of potential topics to include in
survey questions, followed by the development of a large number
of questions, which overlap and then reduce to a smaller number
of higher performing questions based on field testing.70,71 For
example, a question on the presence or absence of myocardial
infarction could be asked several ways, and the question that
proves most valid and reliable in testing is retained and the other
forms of the question are discarded. Although 7 studies
mentioned that their questionnaires were rephrased to optimize
clarity and comprehension,27,32,33,38,44,47,59 there were no studies
that started intentionally with a larger question bank that was
then reduced down to reliable and valid questions.
This study should be interpreted in the context of its limitations.
Although an extensive search in 5 electronic database was con-
ducted with the help of an experienced librarian, the possibility of
missing studies cannot be excluded. Comorbidity data is collected
in a large proportion of medical studies, and therefore inclusion and
exclusion criteria had to be defined to allow for reasonable iden-
tification of self-reported comorbidity instruments. The goal was to
identify studies that primarily focused on instrument development
or validation. It is possible that comorbidity questionnaires that
were used but did not have any description of their development,
validity, or reliability in the abstract or title could have been missed
in the present search strategy, such as instruments in the gray
literature. Additionally, studies that may have subsequently used
information from a comorbidity instrument to predict an outcome
in a general study without mention of the instrument itself in the
abstract could have been missed with this search strategy. The
presence of 2 independent reviewers to conduct the study selec-
tion, data extraction, and overall interpretation added to the ac-
curacy of the review process.
This systematic review was inspired by international efforts
(eg, the International Consortium for Health Outcomes Measure-
ment [ICHOM],3 the United States Agency for Healthcare Research
and Quality (AHRQ),72 and the Registry of Patient Registries
project73) to harmonize collection and format of outcome mea-
sures. These outcome measures can include suggested outcome
domains, measurement tools, and predictor variables for risk
adjustment for a given medical condition. Among these risk-
adjustment factors are morbidity variables, which can be
collected and analyzed using various methods. Minimal standards
for consistent capture of morbidity data are essential for fair
benchmarking for VBHC or public reporting or outcomes. Patient-
reported morbidity instruments can be used internationally and
among hospitals with no or different electronic medical records
and administrative data structure. Additionally, these instruments
could be used to bolster the medical record. Future researchshould focus on the capture of complete morbidity data for the
purposes of more robust risk adjustment, a key component of fair
benchmarking for VBHC.Conclusions
In summary, this systematic review found ten self-reported
morbidity instruments, with the Patient-Reported Charlson Co-
morbidity Index11 and the Self-Administered Comorbidity Ques-
tionnaire27 being the most frequently cited instruments. Within
each included instrument, there was significant variability in the
reliability of patient-reported comorbidities based on the comor-
bid condition. Further research is needed to determine whether
patient-reported comorbidity data should be used to bolster
medical records data or serve as a stand-alone entity for risk
adjustment of observational outcomes data.Acknowledgments
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